...
首页> 外文期刊>International Journal of Radiation Oncology, Biology, Physics >Operable Stages IB and II cervical carcinomas: a retrospective study comparing preoperative uterovaginal brachytherapy and postoperative radiotherapy.
【24h】

Operable Stages IB and II cervical carcinomas: a retrospective study comparing preoperative uterovaginal brachytherapy and postoperative radiotherapy.

机译:可操作的IB和II期宫颈癌:一项回顾性研究,比较了术前子宫阴道近距离放射治疗和术后放疗。

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE: To evaluate our data concerning prognostic factors and treatment toxicity in a series of operable cervical carcinomas.METHODS AND MATERIALS: Between May 1972 and January 1994, 414 patients with cervical carcinoma, staged according to the 1995 FIGO staging system (286 Stage IB1, 38 Stage IB2, 56 Stage IIA, and 34 Stage IIB with 1/3 proximal parametrial involvement), underwent radical hysterectomy with (n = 380) or without (n = 34) bilateral pelvic lymph node dissection (N+: n = 68). Group I included 168 patients who received postoperative radiation therapy (RT): 64 patients had low-dose-rate vaginal brachytherapy with a median total dose (MTD) of 50 Gy; 93 patients had external beam pelvic RT (EBPRT) with an MTD of 45 Gy over 5 weeks, followed by low-dose-rate vaginal brachytherapy (MTD: 20 Gy); and 11 patients had EBPRT alone (MTD: 50 Gy over 6 weeks). Group II included 246 patients treated with preoperative low-dose-rate uterovaginal brachytherapy (MTD: 65 Gy); 32 of these 246 patients also received postoperative EBPRT (MTD: 45 Gy over 5 weeks) delivered to the parametria and pelvic nodes. Mean follow-up from the beginning of treatment was 106 months.RESULTS: First events included isolated locoregional recurrences (35 patients), isolated distant metastases (27 patients), and locoregional recurrences with synchronous metastases (13 patients). The 10-year disease-free survival (DFS) rate was 88% for Stage IB1, 44% for Stage IB2, 65% for Stage IIA, and 48% for Stage IIB. Multivariate analysis showed that independent factors influencing the probability of DFS were as follows: cervical site (exocervical or endocervical vs. both endo- and exocervical, relative risk [RR]: 1.77, p = 0.047), vascular space invasion (no vs. yes, RR: 1.95, p = 0.041), age (>51 years vs. 1 cm: 83% vs. 41%, respectively, p = 0.001). The overall postoperative complication rate was 10% in Group I and 9% in Group II (p = 0.7). The rate of postoperative ureteral complications requiring surgical intervention was lower in Group I than in Group II (0.6% vs. 2.3%, respectively, p = 0.03). The overall 10-year rate for Grade 3 and 4 late radiation complications was 10.4%. Postoperative EBPRT significantly increased the 10-year rate for Grade 3 and 4 late radiation complications (yes vs. no: 22% vs. 7%, respectively, p = 0.0002).CONCLUSION: The prognosis for patients with cervical carcinoma was not influenced by the sequence of adjuvant RT (preoperative uterovaginal brachytherapy vs. postoperative RT) for Stages IB, IIA, and IIB with 1/3 proximal parametrial involvement. However, postoperative EBPRT increased the risk of late radiation complications.
机译:目的:评估我们在一系列可手术宫颈癌中的预后因素和治疗毒性的数据。方法和材料:1972年5月至1994年1月之间,根据1995年FIGO分期系统分期的414例宫颈癌患者(286期IB1, 38例IB2、56例IIA和34例IIB期,有1/3的近端子宫旁膜受累,行根治性子宫切除术(n = 380)或不行(n = 34)双侧盆腔淋巴结清扫术(N +:n = 68)。第一组包括168例接受术后放射治疗(RT)的患者:64例低剂量率阴道近距离放射治疗,中位总剂量(MTD)为50 Gy; 93例患者在5周内的MTD为45 Gy,行体外盆腔RT(EBPRT)治疗,随后进行低剂量率的阴道近距离放疗(MTD:20 Gy); 11例仅接受EBPRT(MTD:6周内50 Gy)。第二组包括246例术前低剂量率子宫阴道近距离放射治疗(MTD:65 Gy);在这246名患者中,有32名也接受了术后EBPRT(MTD:5周内为45 Gy),分娩至子宫旁膜和盆腔淋巴结。从治疗开始平均随访106个月。结果:首发事件包括局部复发(35例),远处转移(27例)和同步转移局部复发(13例)。 IB1期的10年无病生存率(DFS)为88%,IB2期为44%,IIA期为65%,IIB期为48%。多变量分析表明,影响DFS可能性的独立因素如下:子宫颈部位(子宫颈或子宫颈与子宫颈和子宫颈相对,相对风险[RR]:1.77,p = 0.047),血管空间侵犯(否或是) ,RR:1.95,p = 0.041),年龄(> 51岁vs. 1厘米:分别为83%和41%,p = 0.001)。 I组的总术后并发症发生率为10%,II组为9%(p = 0.7)。 I组的需要手术干预的输尿管并发症发生率低于II组(分别为0.6%和2.3%,p = 0.03)。 3级和4级晚期放射并发症的总10年率为10.4%。术后EBPRT显着提高了3级和4级晚期放射并发症的10年发生率(是vs.否:22%vs. 7%,p = 0.0002)。结论:宫颈癌患者的预后不受以下因素的影响IB,IIA和IIB期伴有1/3子宫旁旁膜受累的辅助RT的顺序(术前子宫阴道近距离放射治疗与术后RT)。但是,术后EBPRT增加了晚期放射并发症的风险。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号